01—Abstract
Summary
Summary of the 10-K filed February 19, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation reported record net sales of $3,457.5 milliona for 2025, up 6% from $3,268.8 million in 2024, with organic sales growth of 1%.
Reported diluted EPS attributable to IDEX was $6.41b, down from $6.64, while adjusted diluted EPS rose to $7.95 from $7.89. Management attributed the year's results to positive price across all segments and productivity gains from restructuring and cost containment, offset by lower volumes in the FMT and FSDP segments, higher interest expense, a higher effective tax rate of 23.7%, and higher acquisition-related amortization of $130.7 million. Cash generation remained strong, with operating cash flow of $680.4 million and free cash flow of $616.8 million.
The company returned $248 millionc through share repurchases and $213 million in dividends. Cash and cash equivalents were $580.0 million, total borrowings were $1,829.8 million, and the Revolving Facility had $568.6 million of net availability at year-end. Covenant calculations showed an interest coverage ratio of 13.13 to 1 and a leverage ratio of 1.96 to 1, against required levels of 3.0 to 1 and 3.50 to 1, respectively.
Looking ahead, management expects continued growth in HST, supported by data center, semiconductor, space and defense, and food and beverage and pharmaceutical demand. Industrial and automotive markets have not yet recovered, core industrial markets in FMT are tracking flat, and near-term headwinds are expected to persist in FSDP, particularly in Fire & Safety outside the United States and in Dispensing capital spending. The company also reported that Mr. Gillen joined as Senior Vice President and Chief Financial Officer in January 2026.
02—Key points
Key Highlights
- Net sales reached a record $3,457.5 million, up 6% overall and 1% organically, with positive price across all segments.
- Reported diluted EPS attributable to IDEX was $6.41, down 3% from $6.64, while adjusted diluted EPS rose 1% to $7.95.
- Operating cash flow was $680.4 million and free cash flow was $616.8 million, with free cash flow at 103% of adjusted net income.
- The company repurchased $248 million of shares and paid $213 million in dividends during 2025; $924.7 million of repurchase authorization remained at year-end.
- Interest expense - net rose to $64.4 million from $44.5 million, driven by higher debt tied to the Mott acquisition, and the effective tax rate increased to 23.7% from 21.1%.
- Balance sheet covenants were met comfortably, with an interest coverage ratio of 13.13 to 1 and a leverage ratio of 1.96 to 1 against requirements of 3.0 to 1 and 3.50 to 1.
- Goodwill and intangible assets total $3,414.5 million and $1,247.4 million, respectively, and no impairment was noted in the October 31, 2025 annual test.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Idex kept $0.14.
- Revenue$3.46B100.0%
- Cost of revenue−$1.92B55.5%
- Gross profit$1.54B44.5%
- Operating costs−$839.5M24.3%
- Operating income$699.3M20.2%
- Interest, other & tax−$216.1M6.3%
- Net income$483.2M14.0%
Where FY2025 revenue went
$3.46B- Cost of revenue: $1.92B, 55% of revenue
- SG&A: $818.8M, 24% of revenue
- Net income: $483.2M, 14% of revenue
- R&D: $70.0M, 2.0% of revenue
- Interest, other & tax: $216.1M, 6.3% of revenue
Kept 14% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 19, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $3.46B$3.27B | +5.8% |
| Cost of Revenue | $1.92B$1.82B | +5.2% |
| Gross Profit | $1.54B$1.45B | +6.5% |
| R&D Expenses | $70.00M$67.40M | +3.9% |
| SG&A Expenses | $818.80M$758.70M | +7.9% |
| Operating Income | $699.30M$677.20M | +3.3% |
| Net Income | $483.20M$505.00M | −4.3% |
| EPS (Basic) | $6.41$6.66 | −3.8% |
| EPS (Diluted) | $6.41$6.64 | −3.5% |
| Shares Outstanding (Basic) | 75.30M75.70M | −0.5% |
| Shares Outstanding (Diluted) | 75.30M75.90M | −0.8% |
05—Questions
Frequently Asked Questions
How did IDEX perform in 2025 compared with 2024?
Net sales rose 6% to a record $3,457.5 million, with organic growth of 1% driven by price. Gross margin improved to 44.5% from 44.2%. Operating income increased 3% to $699.3 million, but reported diluted EPS declined 3% to $6.41 due to higher interest expense, a higher tax rate and increased amortization.
What segment trends drove results in 2025?
HST grew net sales 15% to $1,495.5 million, with organic growth of 4% from data center, semiconductor and space and defense volumes. FMT net sales declined 1% to $1,224.0 million on lower chemical, energy and agriculture volumes, though Adjusted EBITDA margin rose to 33.2%. FSDP net sales were essentially flat at $745.3 million, with lower Dispensing and Fire & Safety volumes.
What is the company's outlook for 2026?
Management expects continued growth in HST, supported by data center, semiconductor, space and defense, and food and beverage and pharmaceutical demand. Water businesses in FMT are expected to show continued momentum, while core industrial markets are tracking flat. FSDP faces near-term headwinds from Fire & Safety markets outside the U.S. and subdued Dispensing capital spending.
How strong is IDEX's liquidity and debt position?
At December 31, 2025, cash and cash equivalents were $580.0 million, of which $526.2 million was held outside the United States. Total borrowings were $1,829.8 million, and the $800 million Revolving Facility had $568.6 million of availability. Management believes cash, operating cash flow and the Revolving Facility will be sufficient for its cash requirements for the foreseeable future.
What are the key risks highlighted in the filing?
The filing highlights risks including competition, raw material and component cost changes including tariffs, cybersecurity incidents, AI-related uncertainty, international operations and currency movements, interest rate changes, and the potential for goodwill and intangible asset impairments given that these represented a significant portion of total assets. It also notes that asbestos-related claims involving seven subsidiaries remain pending, though the company does not believe they will have a material adverse effect.
06—Continue